Treatment of type 2 diabetes with the SGLT2 inhibitor empagliflozin led to a reduction of cardiovascular mortality by 38% and of hospitalizations because of heart failure by 35% [130], similar to cardiovascular outcome trials with dapagliflozin and canagliflozin [131, 132]. This evidence concerns the gene SLC5A2 and heart failure.